Home › Funds › Vestal Point Capital, LP › CBIO

Vestal Point Capital, LP position in CBIO

CRESCENT BIOPHARMA INC. · Health Care

Vestal Point Capital, LP reported holding 1,630,000 shares of CBIO (CRESCENT BIOPHARMA INC.) in its Q2 2026 13F filing — a position valued at US$29.3M, representing 0.69% of its reported portfolio and ranking #36 among its reported holdings. Vestal Point Capital, LP has disclosed CBIO holdings in 3 of the last 3 reported quarters, going back to Q4 2025.

Latest position (Q2 2026)1.63M sh
Reported value held$29.34M
Portfolio Weight0.69%
First reportedQ4 2025
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Vestal Point Capital, LP's CBIO position evolved

Vestal Point Capital, LP first disclosed a stake in CBIO in Q4 2025 at 1,500,000 shares (US$17.8M). The position peaked in Q2 2026 at 1,630,000 shares, worth US$29.3M. Across 3 filings, Vestal Point Capital, LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 1,630,000 shares valued at US$29.3M — an increase of 130,000 shares quarter over quarter..

Quarter by quarter

QuarterSharesValueChange
Q4 2025 1.50M $17.79M New
Q1 2026 1.50M $27.55M Hold
Q2 2026 1.63M $29.34M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About CBIO and 13F data

CBIO (CRESCENT BIOPHARMA INC.) is a Health Care company. 71 other funds we track also report a position in CBIO — the largest reported positions include BVF INC/IL (US$49.5M), Fairmount Funds Management LLC (US$49.5M), Venrock Adviser, LLC (US$38.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding CBIO

All CBIO fund holders →

FAQ

How long has Vestal Point Capital, LP held CBIO?

Vestal Point Capital, LP has disclosed CBIO holdings in 3 of the last 3 reported quarters, going back to Q4 2025.

What is Vestal Point Capital, LP's current position in CBIO?

As of Q2 2026, Vestal Point Capital, LP holds 1.63M shares of CBIO (CRESCENT BIOPHARMA INC.), valued at $29.34M, representing 0.69% of its reported portfolio and ranking #36.

Has Vestal Point Capital, LP been buying or selling CBIO?

In the latest 13F filing (Q2 2026), Vestal Point Capital, LP increased its position in CBIO. The position peaked in Q2 2026 at 1.63M shares.

Which other funds hold CBIO?

Other major institutional holders of CBIO include BVF INC/IL, Fairmount Funds Management LLC, Venrock Adviser, LLC, among 71 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.